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Abstract 
Apremilast is an oral phosphodiesterase IV inhibitor recently registered for the treatment of 
psoriasis and psoriatic arthritis in Switzerland and other countries. Even though it offers only 
moderate efficacy compared to biologics, many patients prefer drugs given by the oral route. 
Apremilast is frequently used in private practice, as it showed no relevant safety signals in 
clinical trials and often, laboratory tests are omitted completely. Here we report a patient 
who developed acute lymphopenia and worsening of psoriasis during apremilast treatment, 
which resolved with discontinuation of apremilast. We suggest that at least in prospective 
registries, that regular monitoring of laboratory surrogate markers should be performed on a 
long-term basis to detect rare but potentially important safety signals. 
 © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Apremilast is an oral phosphodiesterase IV (PDE4) inhibitor recently registered for the 
treatment of psoriasis and psoriatic arthritis. Apremilast is frequently used in private prac-
tice, as it showed no relevant safety signals in clinical trials and currently, no laboratory tests 
are recommended during treatment. 
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Case Report 
Here we report the case of a man in his 40ies with plaque-type psoriasis for 3 years. He 
presented with a Psoriasis Area and Severity Index (PASI) of 10.3 and a Dermatology Life 
Quality Index of 8. Previous treatments included topical combined calcipotriol/betametha-
sone (Daivobet®) and UVB narrowband therapy. His medical history included hypercholes-
terinemia and Gilbert-Meulengracht disease with slightly elevated bilirubin of 23 μmol/L 
(reference <21 μmol/L). A differential blood count showed a mild lymphopenia of 1.05 × 
109/L (reference 1.5–4.0 × 109/L) of unknown etiology. Other laboratory investigations 
were inconspicuous. 
Treatment with apremilast was initiated using the recommended titration scheme. One 
month later, the lymphopenia had worsened to 0.64 × 109/L without any clues suggestive of 
an underlying event such as a viral infection, for example. A HIV test was negative and the 
CD4/CD8 ratio was normal. Psoriasis plaques had worsened at 1 month of therapy, resulting 
in a higher PASI of 16.6. Apremilast treatment was interrupted, and 2 days later, lymphocyte 
counts increased to 0.78 × 109/L and 3 weeks later to 1.14 × 109/L (Fig. 1). Leukocyte and 
especially neutrophil counts had almost doubled during apremilast therapy, remaining, 
however, within normal range, and returned to baseline levels after cessation of apremilast. 
A topical treatment with clobetasol propionate 0.05% (Clarelux® foam) was initiated and 
PASI improved to a value of 12 within 4 weeks. The negative temporal correlation of the 
lymphocyte counts with apremilast led us to the clinical conclusion that the drug might have 
been causally related to the lymphopenia. Hence, apremilast was not reinitiated and another 
treatment was introduced. 
Discussion 
Lymphopenia during apremilast treatment in humans has not been reported before and 
we expect that our observation is a rare event. Clinical trials showed consistently good la-
boratory safety data, leading to some expert recommendations that blood sample monitor-
ing can be omitted [1]. Newer guidelines, such as the Swiss S1, recommend several obligato-
ry and optional laboratory safety checks before treatment initiation [2]. 
In monkey studies with apremilast, lymphopenia and neutrophilia were reported but 
evaluated as negligible in magnitude and/or in the range of pretest values [3]. In mice and 
rat studies, lymphopenia and neutrophilia and also CRP elevation and albumin decrease 
were associated with arteritis and perivascular inflammation in various tissues. CRP and 
albumin were normal during apremilast in our patient. 
In general, with PDE4, inhibition by apremilast through accumulation of cAMP leads to 
inhibition of pro-inflammatory cytokines like TNF-α, IL-17, IFN-γ, and IL-23, whereas IL-10 
is increased [4]. Apremilast acts nonselective on PDE4 isoforms A–D. T lymphocytes (CD4 
and CD8) contain mostly the PDE4B and to a lesser extent the PDE4A subtype as well as 
PDE3 and PDE7 [5]. In COPD patients, treatment with cilomilast, a PDE4 inhibitor selective 
for PDE4D [6], or roflumilast, a PDE4 inhibitor almost nonselective on PDE4 isoforms be-
sides being less selective for PDE4C [7], airway inflammation by lymphocytes and other cells 
like neutrophils was reduced. There is inconsistent evidence that PBMCs of atopic patients 
have a higher susceptibility to PDE inhibitors [8]. Interestingly it was shown that structural 
and molecular differences in the M-loop region of PDE4 can enhance the potency of its lig-
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ands [9]. In summary, it could be speculated that a structural variance in PDE4 or an overex-
pression of a certain isotype of PDE4, like PDE4B, lead to reduced cell numbers. 
From our single case, no conclusions on a causal effect of apremilast on lymphocyte 
counts can be drawn. As the clinical use of apremilast increases, it will be interesting to see 
whether our observation will also be made by others. Such safety signals would not neces-
sarily be seen in clinical trials, because clinical trials include only highly selected patient 
populations that may not represent the general population. Hence, reporting of rare clinical 
observations in the post-marketing phase and ideally long-term registry data are crucial for 
developing a solid basis for recommendations on whether laboratory investigations for new 
drugs should be routinely performed or not. 
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Fig. 1. Lymphocyte count versus PASI score. This case shows the course of lymphocytes compared to PASI 
during apremilast treatment. Lymphocytes in n × 109/L. 
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